BIOMAT Database Logo BIOMAT Database Logo

[The effect of doxazosin on blood pressure, lipids, fibrinogen and plasminogen activator inhibitor. A comparative study among smokers and non-smokers with essential hypertension]. 1991

L N Daae, and P Kierulf, and B Brusletto, and A Westheim, and I Holme, and J O Syvertsen
Klinisk kjemisk avdeling, Ullevål sykehus, Oslo.

Hypertensive cigarette smokers run particularly high risk of coronary heart disease. Doxazosin, which has beneficial effects on haemodynamic factors and lipid metabolism, may be a suitable agent for treating these patients. The effects on blood pressure and metabolic parameters were investigated in a 16-week, open, parallel, comparative study comprising 64 heavy cigarette smokers and 69 non-smokers who received doxazosin after four weeks on placebo. Eight patients (three smokers and five non-smokers) dropped out due to adverse effects. Blood pressure was significantly reduced in both groups, but there was no change in heart rate. Doxazosin induced a decrease in the triglyceride, total cholesterol and LDL-cholesterol levels, and an increase in HDL-cholesterol concentration. Thus, doxazosin has favourable effects on atherogenic factors in smoking hypertensive patients. There was also a significant lowering of plasma fibrinogen levels and plasminogen activator inhibitor (PAI-1) concentration in non-smokers.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011224 Prazosin A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION. Furazosin,Minipress,Pratsiol,Prazosin HCL,Prazosin Hydrochloride,HCL, Prazosin,Hydrochloride, Prazosin
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012907 Smoking Willful or deliberate act of inhaling and exhaling SMOKE from burning substances or agents held by hand. Smoking Behaviors,Smoking Habit,Behavior, Smoking,Behaviors, Smoking,Habit, Smoking,Habits, Smoking,Smoking Behavior,Smoking Habits
D015849 Plasminogen Inactivators Important modulators of the activity of plasminogen activators. The inhibitors belong to the serpin family of proteins and inhibit both the tissue-type and urokinase-type plasminogen activators. Plasminogen Activator Inhibitor,Plasminogen Activator Inhibitors,Endothelial Plasminogen Activator Inhibitors,Placental Plasminogen Activator Inhibitors,Plasminogen Activator Inhibitors, Endothelial,Plasminogen Activator Inhibitors, Placental,Activator Inhibitor, Plasminogen,Inactivators, Plasminogen,Inhibitor, Plasminogen Activator,Inhibitors, Plasminogen Activator

Related Publications

L N Daae, and P Kierulf, and B Brusletto, and A Westheim, and I Holme, and J O Syvertsen
Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension.
May 1987, The American journal of cardiology,
L N Daae, and P Kierulf, and B Brusletto, and A Westheim, and I Holme, and J O Syvertsen
Effect of doxazosin monotherapy on blood pressure and plasma lipids in patients with essential hypertension.
April 1988, American journal of hypertension,
L N Daae, and P Kierulf, and B Brusletto, and A Westheim, and I Holme, and J O Syvertsen
Relationships between fibrinogen, plasminogen activator inhibitor-1, and their gene polymorphisms in current smokers with essential hypertension.
June 2003, Thrombosis research,
L N Daae, and P Kierulf, and B Brusletto, and A Westheim, and I Holme, and J O Syvertsen
Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension.
January 1995, Angiology,
L N Daae, and P Kierulf, and B Brusletto, and A Westheim, and I Holme, and J O Syvertsen
Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor-1 levels in patients with essential hypertension.
October 1998, Cardiovascular drugs and therapy,
L N Daae, and P Kierulf, and B Brusletto, and A Westheim, and I Holme, and J O Syvertsen
Combined effect of a low fat diet and doxazosin on blood pressure control and blood lipids. Hunter Hypertension Research Group.
December 1994, Journal of human hypertension,
L N Daae, and P Kierulf, and B Brusletto, and A Westheim, and I Holme, and J O Syvertsen
Long-term effects of doxazosin and atenolol on serum lipids and blood pressure in hypertensive smokers.
September 1990, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
L N Daae, and P Kierulf, and B Brusletto, and A Westheim, and I Holme, and J O Syvertsen
Effect of hypotensive drugs on the circadian blood pressure pattern in essential hypertension: a comparative study.
December 1997, Cardiovascular drugs and therapy,
L N Daae, and P Kierulf, and B Brusletto, and A Westheim, and I Holme, and J O Syvertsen
Association of fibrinogen and plasminogen activator inhibitor-1 with diabetes mellitus.
January 2022, Pakistan journal of pharmaceutical sciences,
L N Daae, and P Kierulf, and B Brusletto, and A Westheim, and I Holme, and J O Syvertsen
Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen: Effect of dieting with or without exercise in overweight postmenopausal women.
March 1996, Arteriosclerosis, thrombosis, and vascular biology,
Copied contents to your clipboard!